tirzepatide legal battle court UPDATE [March 7, 2025]: OFA takes case to appeals as evolves FDA's tirzepatide decision creates uncertainty – Lilly Takes Four Compounders to

Overexpression of Sirt6 is a novel biomarker of malignant human colon carcinoma

The company positions itself as an affordable alternative to brand-name medications like Zepbound and Mounjaro

Semaglutide emerged as one of the most influential peptides in this area, helping researchers gain a deeper understanding of GLP-1 receptor signaling

An important finding from animal studies: the minimally effective weight-based dosages determined in rats (2.5-5 ml per kg) are considerably higher than typical human clinical doses

The incident led to a class action lawsuit, which the company has agreed to settle for $30 million

Lifestyle remains foundational: Medication is a tool